Ropivacaine
- Generic Name
- Ropivacaine
- Brand Names
- Naropin
- Drug Type
- Small Molecule
- Chemical Formula
- C17H26N2O
- CAS Number
- 84057-95-4
- Unique Ingredient Identifier
- 7IO5LYA57N
- Background
Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
- Indication
Ropivacaine is indicated in adult patients for the induction of regional or local anesthesia for surgery or acute pain management.
- Associated Conditions
- Acute Pain, Postoperative pain
- Associated Therapies
- Surgical anesthesia therapy
Continuous TQL Block for Elective Cesarean Section
- Conditions
- Interventions
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Zealand University Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT03663478
- Locations
- π©π°
Department of anaesthesiology, Roskilde, Denmark
TAP-Block in Abdominal Aortic Surgery
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Centre Hospitalier Universitaire Dijon
- Target Recruit Count
- 50
- Registration Number
- NCT03657979
- Locations
- π«π·
Cardiovascular and thoracic surgery unit, CHU Dijon, Dijon Cedex, France
Transmuscular Quadratus Lumborum Block for Total Laparoscopic Hysterectomy.
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Zealand University Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT03650998
- Locations
- π©π°
Zealand University Hospital, Department of Anaesthesiology, Roskilde,, Zealand, Denmark
Postoperative Analgesic Efficacy of Continuous Wound Infusion After Laparoscopy
- Conditions
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Kangbuk Samsung Hospital
- Target Recruit Count
- 66
- Registration Number
- NCT03645304
- Locations
- π°π·
Kangbuk Samsung Hospital, Seoul, Korea, Republic of
Scalp Infiltration With Methylprednisolone Plus Ropivacaine for Post-Craniotomy Pain in Children
- Conditions
- Interventions
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- Beijing Tiantan Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT03636165
The Effect of the Transversus Abdominis Plane Block to Postoperative Analgesia for Cesarean Section
- Conditions
- Interventions
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Gia Dinh People Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT03634111
- Locations
- π»π³
THANG Nguyen Trong, Ho Chi Minh, Vietnam
Evaluation of Trigeminal Nerve Blockade
- Conditions
- Interventions
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 40
- Registration Number
- NCT03632044
- Locations
- πΊπΈ
UF Health, Gainesville, Florida, United States
Pre-emptive Scalp Infiltration With Dexamethasone Plus Ropivacaine for Postoperative Pain After Craniotomy
- Conditions
- Interventions
- First Posted Date
- 2018-08-07
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Beijing Tiantan Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT03618264
- Locations
- π¨π³
Beijing Tiantan Hospital, Beijing, China
The Effect and Safety of the Four Points Transversus Abdominis Plane Block
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Gia Dinh People Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03598192
- Locations
- π»π³
Binh Huynh, Ho Chi Minh City, Ho Chi Minh, Vietnam
Phase I/II Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC590 for Postsurgical Pain Management
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2021-07-14
- Lead Sponsor
- Taiwan Liposome Company
- Target Recruit Count
- 65
- Registration Number
- NCT03591146
- Locations
- πΊπΈ
JBR Clinical Research, Draper, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.